SLC12A5 and neoplasm: The majority of T‐cell dysfunction markers were highly expressed in tumours with low expression of SLC12A5, which also had a higher immune evasion score demonstrating the potentials of SLC12A5 on predicting response to immunotherapy (Figure 8D, Figure S4C).